Sinocare Inc. Class A

Sinocare Inc. Class A

SSZSE:300298
17.80
CNY
-0.35
(-1.93%)
0.45EPS
34.70P/E
9.08BMarket Cap
Apr 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.93
1.46
1.72
1.63
2.12
2.78
3.15
3.6
4.21
7.08
7.29
8.02
8.47
9.36
Basic EPS, GAAP
0.34
0.53
0.38
0.24
0.53
0.56
0.44
0.33
0.19
0.8
0.51
0.59
0.17
0.47
Free Cash Flow per Basic Share
0.02
0.22
0.17
0.3
0.3
0.14
0.18
0.41
0.14
0.65
0.7
0.8
0.74
- -
Dividend per Share
0.14
0.18
0.18
0.19
0.25
0.25
0.31
0.32
0.24
0.29
0.26
0.24
0.25
0.03
Book Value per Share
1.97
2.28
2.53
2.62
2.84
4.64
4.69
4.84
4.93
5.52
5.46
5.95
5.56
5.75
Tangible Book Value per Share
1.91
2.23
2.42
2.51
2.73
3.55
3.63
3.82
3.8
2.81
2.96
3.48
3.39
3.65
Basic Weighted Avg Shares
484
374
376
488
488
558
564
559
561
558
557
554
550
539
Sales/Revenue/Turnover
449
545
646
796
1,033
1,551
1,778
2,015
2,361
3,952
4,059
4,443
4,659
5,046
Operating Margin (%)
32.69
32.3
17.62
19.47
28.96
21.7
22.67
21.2
15.64
12.22
11.32
11.76
6.28
11.36
Depreciation Expense
5
9
15
22
32
51
93
82
105
180
204
216
197
- -
Net Income, GAAP
165
197
144
115
258
310
251
187
108
447
284
326
93
253
Effective Tax Rate (%)
13.36
14.27
11.49
16.01
15.46
12.36
16.84
24.57
22.55
8.9
21.21
12.5
70.19
25.12
Profit Margin (%)
36.81
36.21
22.26
14.48
24.97
20.02
14.1
9.27
4.56
11.3
7.01
7.34
1.99
5.02
Working Capital
827
925
667
459
530
986
887
1,224
851
735
710
688
309
592
LT Debt
19
19
8
- -
15
11
147
507
509
960
892
467
204
352
Total Equity
946
1,111
1,240
1,278
1,390
2,623
2,649
2,741
2,792
3,343
3,471
3,770
3,444
3,504
Return on Invested Capital (%)
15.75
15.99
10.25
4.83
18.63
14.97
8.43
5.92
3.29
8.58
4.79
7.92
0.45
5.25
Return on Capital (%)
17.03
17.57
11.05
8.63
19.31
15.43
9.34
6.42
3.83
10.2
9.08
7.61
3.94
6.46
Return on Common Equity (%)
18.46
19.18
12.24
9.17
19.36
15.47
9.51
6.94
3.9
15.14
9.19
10.14
2.86
7.74

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
526
612
707
LT Borrowings
274
361
351
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
560
557
557
Market Capitalization
8,891
7,768
9,077

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,319
2,512
2,793
Cash, Cash Equivalents & STI
862
1,016
1,119
Accounts Receivable, Net
543
574
548
Inventories
730
740
802
Total Current Liabilities
1,940
2,040
2,202
Payables & Accruals
- -
- -
- -
ST Debt
526
612
707
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.04%
5.08%
-8.63%
Free Cash Flow
56.65%
64.28%
-8.62%
Net Income, GAAP
25.92%
35.89%
-71.61%
Sales/Revenue/Turnover
23.28%
20.32%
4.87%
Total Cash Common Dividend
8.78%
-4.08%
2.21%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,014
1,119
1,049
1,261
4,443
2025
1,042
1,222
- -
1,206
4,659
2026
1,239
1,298
1,303
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.21
0.1
0.13
0.59
2025
0.13
0.2
- -
-0.22
0.17
2026
0.18
0.23
0.28
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.21
0.01
0.02
0.24
2025
- -
0.22
- -
0.02
0.25
2026
- -
- -
- -
- -
- -

Company Description

CEO
Xin Yi Li
Full Time Employees
5,010
Sector
Health technology
Industry
Medical specialties
Address
No. 265 Guyuan Road Changsha HN China 410205
IPO Date
Mar 5, 2012
Business
Sinocare Inc. (300298.SZ) develops, manufactures and markets blood glucose monitoring systems and other rapid diagnostic testing products for chronic disease management, primarily diabetes; core offerings include blood glucose meters such as the Gold AQ Plus series, Safe AQ Max series and One Sinocare series, test strips, uric acid meters including the UG series, EA-11 and UA-I models, glycated hemoglobin analyzers, blood pressure monitors, continuous glucose monitoring (CGM) systems like the iCan CGM, HbA1c testing systems and diabetes management software; the company also provides health management services and point-of-care testing solutions to patients and medical institutions. Founded in 2002 and headquartered in Changsha, Hunan Province, China, Sinocare operates nine global research, development and manufacturing sites with presence in over 70 countries and regions, including strong market shares in China where it leads the blood glucose monitoring sector and ranks fourth worldwide; it serves retail, e-commerce, hospital and primary care channels targeting diabetes patients, healthcare professionals and chronic disease sufferers primarily in Asia, Europe, North America and other international markets. Sinocare maintains subsidiaries including Sinocare Meditech Inc. and Trividia Health Inc., the latter resulting from its 2016 acquisitions of Nipro Diagnostics Inc. (renamed Trividia Health) and PTS Diagnostics Inc. to bolster its global blood glucose leadership; in 2024, the company completed the acquisition of Nipro Diagnostics and recently formed a strategic partnership with A. Menarini Diagnostics for exclusive distribution of its third-generation iCan CGM products across more than 20 European jurisdictions under a co-branded label, enhancing its expansion in Europe's growing CGM market.